167090-40-6Relevant academic research and scientific papers
Process development in the synthesis of the ACE intermediate MDL 28,726
Horgan, Stephen W.,Burkhouse, David W.,Cregge, Robert J.
, p. 241 - 247 (1999)
MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the W-trifluoroacetamide of (A,5)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.
Macrocyclic cysteine protease inhibitors and compositions thereof
-
Page/Page column 112, (2016/09/26)
The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions
Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof
-
, (2011/02/18)
The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions
A novel three-step hydroxy-deamination sequence: Conversion of lysine to 6-hydroxynorleucine derivatives
Nevill Jr., C. Richard,Angell, Paul T.
, p. 5671 - 5674 (2007/10/03)
Oxidation of carbamates with catalytic RuO4, generated from RuO2 and NaBrO3, provides the corresponding acyl carbamates, which can be reduced with NaBH4 to provide alcohols. Application of this methodology to L-lysine provides (S)-6-hydroxynorleucine derivatives.
